Novartis Pharmaceuticals UK Ltd

Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442

Patient Information Leaflet last updated on the eMC: 14/10/2010
PIL Trileptal 150 mg, 300 mg, 600 mg Film-coated tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 14/10/2010 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 23/10/2009 and displayed until 14/10/2010
Reasons for adding or updating:
  • Change to date of revision
  • Correction of spelling/typing errors
  • Change due to user-testing of patient information
Updated on 09/07/2009 and displayed until 23/10/2009
Reasons for adding or updating:
  • Change to how the medicine works
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to information about pregnancy or lactation
Updated on 01/09/2008 and displayed until 09/07/2009
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 18/04/2008 and displayed until 01/09/2008
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 19/08/2005 and displayed until 18/04/2008
Reasons for adding or updating:
  • Change to side-effects
  • Change to appearance of the medicine
Updated on 16/02/2005 and displayed until 19/08/2005
Reasons for adding or updating:
  • Change to side-effects
Updated on 15/08/2003 and displayed until 16/02/2005
Reasons for adding or updating:
  • Update to PIL
Updated on 15/08/2003 and displayed until 15/08/2003
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 19/04/2002 and displayed until 15/08/2003
Reasons for adding or updating:
  • New PIL for eMC ie a PIL for an existing product but new to the eMC

Active Ingredients/Generics

 
   oxcarbazepine